AstraZeneca said Enhertu showed a 72 percent lower risk of disease progression or death in women with HER2-positive metastatic breast cancer, compared to other drugs.
The results were presented during a presidential symposium at the European Society of Medical Oncology (ESMO) 2021 Congress.
The trial, which included about 500 patients in multiple countries in Asia, Europe and North and South America, found that the drug “contributes to improving the survival rate”.
But the company indicated that these results are “not final and not yet mature”, which means that more experiments and tests will take place in the coming period.
“Today’s results are groundbreaking,” said Susan Galbraith, executive vice president of research and development in Oncology.
“Enherto improved the survival rate three times, and increased the disease control rate by more than 95 percent, compared to 77 percent for the drug trastuzumab emtancin,” she added.
“This unprecedented data represents a potential paradigm shift in the treatment of metastatic HER2-positive breast cancer, and demonstrates the ability of Enhertu to transform the lives of more patients in the early treatment phase.”